Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Annals of Oncology

• Publication date

  2008-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdn031PMID 18296419
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical Trials and Observations

  2008cited by this paper
• A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma

  2007cited by this paper
• Update of the NCI multiinstitutional phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T-cell lymphoma

  2007cited by this paper
• Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).

  2007cited by this paper
• Revised response criteria for malignant lymphoma.

  2007cited by this paper
• Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities

  2007cited by this paper
• Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-hodgkin’s lymphoma

  2007cited by this paper
• Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

  2007cited by this paper
• Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma

  2007cited by this paper
• Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

  2007cited by this paper
• Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.

  2006cited by this paper
• Romidepsin (Depsipeptide, FK228) Induces Clinically Significant Responses in Treatment-Refractory CTCL: Interim Report of a Phase II Multicenter Study.

  2006cited by this paper
• Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA), in Patients with Leukemia and Myelodysplastic Syndrome.

  2005cited by this paper
• Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.

  2005influential reference
• Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

  2005cited by this paper
• Molecular Pathogenesis of Non-Hodgkin's Lymphoma: the Role of Bcl-6

  2003cited by this paper
• Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

  2003cited by this paper
• Oncogenes and Tumor Suppressors (795 articles) Review Articles (434 articles)

  2003cited by this paper
• CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

  2002cited by this paper
• Acetylation inactivates the transcriptional repressor BCL6

  2002cited by this paper
• CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

  2002cited by this paper
• Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report.

  2001cited by this paper
• International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury.

  1999cited by this paper
• International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury.

  1999cited by this paper
• Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

  1995cited by this paper

• Targeting epigenetic reprogramming in DLBCL and its interaction with the tumor microenvironment for novel therapeutic approaches.

  2025cites this paper
• Venetoclax confers synthetic lethality to chidamide in preclinical models with transformed follicular lymphoma

  2025cites this paper
• Management of T‐cell malignancies: Bench‐to‐bedside targeting of epigenetic biology

  2025cites this paper
• Heterochromatin fidelity is a therapeutic vulnerability in lymphoma and other human cancers

  2025cites this paper
• Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma

  2025cites this paper
• HDAC inhibitors as pharmacological treatment for Duchenne muscular dystrophy: a discovery journey from bench to patients.

  2024cites this paper
• GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma

  2024cites this paper
• Clinical advances in epigenetic therapies for lymphoma

  2023influential citation
• Defining cellular responses to HDAC-selective inhibitors reveals that efficient targeting of HDAC3 is required to elicit cytotoxicity and overcome naïve resistance to pan-HDACi in diffuse large B cell lymphoma

  2023cites this paper
• Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study

  2023cites this paper
• Bortezomib and Vorinostat Therapy as Maintenance Therapy Post-Autologous Transplant for Non-Hodgkin’s Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen

  2023cites this paper
• HIV cure strategies: which ones are appropriate for Africa?

  2022cites this paper
• Impact of Histone Modifications and Their Therapeutic Targeting in Hematological Malignancies

  2022cites this paper
• The Role of HDACs in the Response of Cancer Cells to Cellular Stress and the Potential for Therapeutic Intervention

  2022cites this paper
• The Status and Prospects of Epigenetics in the Treatment of Lymphoma

  2022cites this paper
• Mitigating the Bfl-1-mediated antiapoptotic pathway in diffuse large B cell lymphoma by inhibiting HDACs

  2022cites this paper
• Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies

  2022cites this paper
• Histone Modifications and Their Targeting in Lymphoid Malignancies

  2021influential citation
• A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies

  2021cites this paper
• Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors.

  2021cites this paper
• Clinical and Therapeutic Implications of Epstein–Barr Virus in HIV-Related Lymphomas

  2021cites this paper
• Romidepsin and lenalidomide‐based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts

  2021cites this paper
• CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma.

  2021cites this paper
• Transcriptional and epigenetic landscape of Ca2+-signaling genes in hepatocellular carcinoma

  2021cites this paper
• Refractory DLBCL: Challenges and Treatment.

  2021cites this paper
• First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma.

  2021cites this paper
• Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies

  2021cites this paper
• Epigenetic targeting in lymphoma

  2020cites this paper
• Recent Update of HDAC Inhibitors in Lymphoma

  2020cites this paper
• Advances in targeted therapy for malignant lymphoma

  2020cites this paper
• Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy Resistance

  2020cites this paper
• Histone Deacetylation

  2020cites this paper
• Birth Order, Sibship Size, Childhood Environment and Immune-Related Disorders, and Risk of Lymphoma in Lymphoid Cancer Families

  2020cites this paper
• Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma

  2019cites this paper
• The HDAC6‐selective inhibitor is effective against non‐Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma

  2019cites this paper
• Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma

  2019cites this paper
• Emerging role of histone deacetylase inhibitors in the treatment of diffuse large B-cell lymphoma

  2019cites this paper
• Novel Therapies in Paediatric NHL

  2019cites this paper
• Genetic alterations and their clinical implications in DLBCL

  2019cites this paper
• Resveratrol up-regulates ATP2A3 gene expression in breast cancer cell lines through epigenetic mechanisms.

  2019cites this paper
• Resistance to Histone Deacetylase Inhibitors in the Treatment of Lymphoma

  2019cites this paper
• Meta-analytical methods for estimating outcomes from overall response rate in patients with relapsed/refractory diffuse large B-cell lymphoma

  2019cites this paper
• Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway

  2018cites this paper
• Chromatin dynamics at the core of kidney fibrosis.

  2018cites this paper
• Treatment strategies for diffusive large B-cell lymphoma

  2018cites this paper
• A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B‐cell Lymphoma

  2018cites this paper
• Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives

  2017cites this paper
• A Phase II Exploratory Study of PXD-101 (Belinostat) Followed by Zevalin in Patients with Relapsed Aggressive High-Risk Lymphoma

  2017cites this paper
• Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors

  2017cites this paper
• Silencing heme oxygenase-1 increases the sensitivity of ABC-DLBCL cells to histone deacetylase inhibitor in vitro and in vivo

  2017cites this paper
• BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma.

  2017cites this paper
• Histone deacetylases inhibitors (HDACis) as novel therapeutic application in various clinical diseases

  2017cites this paper
• Beyond genomics - Targeting the epigenome in diffuse large B-cell lymphoma.

  2017cites this paper
• Phase 1 safety and dose escalation of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K in relapsed or refractory lymphoma and multiple myeloma

  2017cites this paper
• CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial

  2017cites this paper
• Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy

  2017cites this paper
• Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.

  2017influential citation
• Metabolic changes in rat serum after administration of suberoylanilide hydroxamic acid and discriminated by SVM

  2017cites this paper
• Innovative targeted therapies for chemorefractory B-cell non-Hodgkin lymphomas

  2017cites this paper
• Clinical Applications of Histone Deacetylase Inhibitors

  2017cites this paper
• Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients

  2016cites this paper
• Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.

  2016cites this paper
• A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520

  2016cites this paper
• Targeting childhood, adolescent and young adult non‐Hodgkin lymphoma: therapeutic horizons

  2016cites this paper
• Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas

  2016cites this paper
• Dual inhibition of histone deacetylases and phosphoinositide 3‐kinases: effects on Burkitt lymphoma cell growth and migration

  2016cites this paper
• Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.

  2016cites this paper
• Emerging Treatment Options for Adolescents and Young Adults with Relapsed or Refractory Lymphoma

  2016cites this paper
• Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia.

  2016cites this paper
• The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.

  2016cites this paper
• Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells

  2015cites this paper
• Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells

  2015cites this paper
• Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs?

  2015cites this paper
• A phase I/II trial of vorinostat (SAHA) in combination with rituximab‐CHOP in patients with newly diagnosed advanced stage diffuse large B‐cell lymphoma (DLBCL): SWOG S0806

  2015cites this paper
• Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.

  2015cites this paper
• Emerging drugs for diffuse large B-cell lymphoma

  2015cites this paper
• Short-Circuiting Gene Regulatory Networks: Origins of B Cell Lymphoma.

  2015cites this paper
• Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy

  2015cites this paper
• Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B‐cell lymphoma not eligible for autologous stem cell transplantation

  2015cites this paper
• Vorinostat Monotherapy for Solid and Hematologic Malignancies

  2015cites this paper
• Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review

  2015influential citation
• Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience

  2014cites this paper
• Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis.

  2014cites this paper
• Histone deacetylase inhibitor prevents cell growth in Burkitt’s lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101

  2014cites this paper
• Safety in Relapsed / Refractory Diffuse Large B-Cell Lymphoma : A Systematic Literature Review

  2014cites this paper
• The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: a clinicopathological study of 262 cases.

  2014cites this paper
• In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells

  2014cites this paper
• R‐CHOP with iodine‐131 tositumomab consolidation for advanced stage diffuse large B‐cell lymphoma (DLBCL): SWOG S0433

  2014cites this paper
• Clinical efficacy and safety in relapsed/refractory diffuse large B-cell lymphoma: a systematic literature review.

  2014cites this paper
• Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update

  2014cites this paper
• Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B‐cell lymphoma

  2013cites this paper
• Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma.

  2013cites this paper
• Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma.

  2013cites this paper
• The Sensitivity of Diffuse Large B-Cell Lymphoma Cell Lines to Histone Deacetylase Inhibitor-Induced Apoptosis Is Modulated by BCL-2 Family Protein Activity

  2013cites this paper
• A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma

  2013cites this paper
• The phosphatidylinositol 3‐kinases (PI3K) inhibitor GS‐1101 synergistically potentiates histone deacetylase inhibitor‐induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal‐regulated kinase pathways

  2013cites this paper
• The role of angiogenesis in human non-Hodgkin lymphomas.

  2013cites this paper
• Panobinostat in lymphoid and myeloid malignancies

  2013cites this paper
• Targeting oncogenic and epigenetic survival pathways in lymphoma

  2013cites this paper
• Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP.

  2013cites this paper